Form 8-K, Sorrento Therapeutics: Phase 2 clinical trial of Abivertinib in COVID-19 patients (October 14, 2020)

Summary

Current report on Form 8-K for an event dated October 14, 2020, filed by Sorrento Therapeutics, Inc. Under Item 8.01, the report states that on October 14, 2020 the company issued a press release announcing that it received clearance from the Brazilian regulatory agency (ANVISA) to proceed with a "Phase 2" clinical trial of Abivertinib in mild, moderate and severe COVID-19 patients. The press release is filed as Exhibit 99.1. Henry Ji signed on October 14, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): October 14, 2020

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. | Other Events.

On October 14, 2020, Sorrento Therapeutics,
Inc. issued a press release announcing that it received clearance from the Brazilian regulatory agency (ANVISA) to proceed with
a Phase 2 clinical trial of Abivertinib in mild, moderate and severe COVID-19 patients. A copy of the press release is filed herewith
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. | Financial Statements and Exhibits.
(d) | Exhibit.
99.1 | Press Release, dated October 14, 2020.
104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: October 14, 2020 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman of the Board, President and Chief Executive Officer

File and source

File

SEC_SRNE_8-K_filed2020-10-14_0001104659-20-114782.htm

Size

25,636 bytes

SHA-256

2a253ae9aaf683e922020e7add3a4245c22c905f088e169b9deace7857d9a37d

Our copy

SEC_SRNE_8-K_filed2020-10-14_0001104659-20-114782.htm

Original

www.sec.gov